Trial Condition(s):
Carcinoma, Renal Cell
Sorafenib as neoadjuvant therapy before cytoreductive nephrectomy in patients with metastatic renal cell carcinoma (SANE)
Bayer Identifier:
16933
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
This local, prospective, multicenter, non-interventional study documents observational data on patients under routine treatment of metastatic RCC with Nexavar before and after cytoreductive nephrectomy. It's planned to better understand the impact of cytoreductive nephrectomy on Nexavar efficacy and possibly to define patients who get the most benefit from Nexavar before cytoreductive nephrectomy.
Inclusion Criteria
- - Male and female patients ≥ 18 years old - Patients with untreated metastatic RCC in whom a decision on neoadjuvant treatment with Nexavar before cytoreductive nephrectomy and in case of clinical feasibility resumption of treatment with Nexavar after nephrectomy has been made at the time of study enrollment - Life expectancy of at least 16 weeks - Patients should have signed informed consent form
Exclusion Criteria
- Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, or in situ cervical cancer. - All contra-indications according to the Russian marketing authorization: -- Hypersensitivity to sorafenib or to any of the excipients. -- Pregnancy and breast-feeding. -- Age less than 18 years.
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many Locations, Russia | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Trial Design
Multicenter, prospective, non-interventional study “Sorafenib as neoadjuvant therapy before cytoreductive nephrectomy in patients with metastatic renal cell carcinoma”
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Maximum percent reduction (based on the minimum post baseline value) in the longest diameter of the primary tumor in response to neoadjuvant Nexavar treatment.Timeframe: up to 2 years
- Response rate of residual disease to Nexavar according to RECIST 1.1 with baseline after cytoreductive nephrectomy.Timeframe: up to 2 years
Secondary Outcome
- Response before cytoreductive nephrectomy according to RECIST 1.1.Timeframe: up to 2 years
- Maximum percent reduction in the sum of longest diameters of target lesions according to RECIST 1.1 while on Nexavar treatment before cytoreductive nephrectomyTimeframe: up to 2 years
- Maximum percent reduction in the sum of longest diameters of target lesions of residual disease after cytoreductive nephrectomy according to RECIST 1.1 while on Nexavar treatment with baseline after cytoreductive nephrectomy.Timeframe: up to 2 years
- Number of participants with AEs, including intra- and postoperative complications, relation to Nexavar treatment, AEs treatment, AEs outcome.Timeframe: up to 2 years
Additional Information
Copyright © Bayer
Powered by
